Search

Additional file 1: Figure S1a. Western blot analysis showing the knockdown of DVL2. Figure S1b. Raw data for western blots in Fig. S1a. Figure S2a. Raw data for western blots in Fig. 2. Figure S2a. Raw data for ChIPdatain Fig. 2. Figure S2b. Raw data for ChIPdatain Fig. 2. Figure S4a. Raw data for western blots in Fig. 4. Figure S4b. Raw data for western blots in Fig. 4.

Additional file 2: Table S1. Protein quantification of western blots of SKBR3 and BT474 cells expressing NTC vs shDVL2 treated with Neratinib. Table S2. Association between DVL-2 protein expression and clinicopathological parameters in HER2-positive breast cancer patient cohort at baseline (N = 24,*p < 0.05). Table S3. Association between DVL-2 protein expression and cancer survival predictors in HER2-positive breast cancer patient cohort (N = 24, p < 0.05). Table S4. Spearman’s rank correlation matrix for DVL2 and clinical parameters and/or survival predictors of breast cancer in 24 HER2-positive breast cancer patients after biopsy at baseline. Table S5. Spearman’s rank correlation matrix for DVL2 and clinical parameters and/or survival predictors of breast cancer at baseline in 14 HER2-positive breast cancer patients who received neoadjuvant chemotherapy (NAC). Table S6. Spearman’s rank correlation matrix for DVL2 and clinical parameters and/or survival predictors of breast cancer after resection in 14 HER2-positive breast cancer patients who received neoadjuvant chemotherapy (NAC). Table S7. Spearman’s rank correlation matrix for DVL2 and clinical parameters and/or survival predictors of breast cancer at baseline biopsy in 10 HER2-positive breast cancer patients who didn’t receive neoadjuvant chemotherapy (NAC). Table S8. ChIP primers used for the study. Table S9. mRNA Primers used for the study. Table S10. Antibodies used for the study.